source
- GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipelineGSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…
- Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s programOn June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…